Skip to main content

patiromer (Veltassa®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA623: Patiromer for treating hyperkalaemia

Medicine details

Medicine name patiromer (Veltassa®)
Formulation 8.4 g, 16.8g and 25.2g powder for oral suspension
Reference number 1991
Indication

Treatment of hyperkalaemia in adult patients with advanced CKD (stage 3-4) on RAAS inhibitor treatment who develop hyperkalaemia

Company Vifor Pharma UK Ltd
BNF chapter Nutrition & blood
Assessment type N/A
Status Excluded due to NICE appraisal
Date of issue 24/05/2018
NICE guidance

TA623: Patiromer for treating hyperkalaemia

Follow AWTTC: